Routine molecular pathology testing for lung cancer began in earnest in 2004, after it was discovered that patients who responded dramatically to the EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, also had detectable EGFR-activating/sensitising mutations in their tumour biopsy specimens [3]. This evidence concerns the gene EGFR and neoplasm.